Nanoparticles and Beyond: Novel Drug Delivery Strategies for Cancer
A major breakthrough in cancer drug delivery took place in 1995, when the FDA approved the first nanodrug, Doxil—a liposomal formulation of doxorubicin engineered to preferentially accumulate in tumors. Since then, the agency has cleared dozens of additional nanoparticle-based cancer therapies.¹ A complementary milestone followed in 2000 with the approval of the first antibody-drug conjugate (ADC), Mylotarg, which used an anti-CD33 antibody to deliver a cytotoxic agent directly to leukemia cells.